Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q1 2026

Biomerica Q1 2026 Results: Net Loss of $1.23M

Biomerica reported a net loss of $1.23 million for the quarter ended August 31, 2026, compared to a small net income of $2,000 in the prior year, driven by a significant decrease in other income and lower gross profit. Total assets increased to $8.07 million from $6.76 million at fiscal year-end, primarily due to $2.23 million in gross proceeds from a private placement of common stock.

Q1 2026 at a glance · $ million
MetricQ1 2026Q1 2025
Revenue1.31.4
Gross profit0.10.4
Profit before tax-1.20.0
Net income-1.20.0
EPS (diluted, $ a share)$-0.37$0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-8.3%
Gross margin8.1%
Operating margin-97.0%
Source

10-Q filed with the SEC, NASDAQ: BMRA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Biomerica Inc: key numbers

Share price
$1.24Close, Nov 17
Market cap
$5.68M
Shares outstanding
4.6MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Biomerica Inc

All →
5:00 PM ET 8-K
Leadership Change

Biomerica Leadership Change

David Moatazedi, a member of the Board of Directors and Chairperson of the Compensation Committee, has determined not to stand for re-election at the company's 2026 Annual Meeting of Stockholders. His departure, effective December 11, 2026, is not due to any dispute or disagreement with the company. Mr. Moatazedi has served on the Biomerica board since December 2022.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.